UPDATE: Wedbush Downgrades Cubist Pharmaceuticals to Neutral, Reiterates $65 PT Following Slight Q3:13 Results Miss

In a report published Thursday, Wedbush analyst Gregory R. Wade downgraded the rating on Cubist Pharmaceuticals CBST from Outperform to Neutral, but reiterated the $65.00 price target. In the report, Wedbush noted, “Cubist reported Q3:13 financials with US CUBICIN revenues of $229.9M, slightly lower than our estimated $238M and only slightly ahead of Q2's $227M. Tightened FY:13 CUBICIN guidance of $885-$900M suggests Q4:13 sales in the range of $225.9-240.9M. CBST reiterated its guidance that the Phase III ceftolozane/tazobactam data in the cUTI setting would be announced later in November and cIAI in late December. An NDA filing is expected about 6 months following potentially positive cIAI data.” Cubist Pharmaceuticals closed on Wednesday at $63.25.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorDowngradesAnalyst RatingsGregory R. WadeWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!